{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-033842","form_type":"8-K","ticker":"ASH","cik":"0001674862","company_name":"ASHLAND INC.","filed_at":"2026-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.858187+00:00","generated_at":"2026-05-16T05:37:43.866253+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ashland Q1 sales down 5% to $386M; narrows FY2026 EBITDA guidance to $400–420M","bullets":["Net loss of $12M (($0.26)/diluted share); Adjusted EPS excl. intangibles amortization $0.26.","Adjusted EBITDA of $58M (15% margin), down 5% YoY; Avoca divestiture reduced sales ~$10M.","Calvert City startup delay and weather disruptions caused ~$10M Adjusted EBITDA hit, isolated to Q2.","Life Sciences grew YoY; Personal Care and Specialty Additives declined; pricing down 2%.","Cash flow from ops $125M (including $103M tax refund); Ongoing Free Cash Flow $26M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-033842","json":"https://secwatch.observer/filing/0001193125-26-033842.json","markdown":"https://secwatch.observer/filing/0001193125-26-033842.md","text":"https://secwatch.observer/filing/0001193125-26-033842.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674862/000119312526033842/0001193125-26-033842-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674862/000119312526033842/ash-20260202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:37:43.866253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}